ArticleFrontiers in oncology2025

Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2).

Tanios Bekaii-Saab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.